Generic semaglutide is still way off for most of us, and that matters
Posted by amber464 in Weight Loss & Metabolic - 27 points, 4 comments.
NBC is talking about why a cheaper generic Ozempic may show up in some countries sooner, but the U.S. likely won’t see one until at least 2031. That’s the part people keep glossing over when they act like pricing is about to magically get normal here.
I’m honestly annoyed by how much hype gets tossed around like lower costs are right around the corner. For folks trying to stay on semaglutide long term, or even just titrate without getting price gouged, that timeline is the whole story. It also lines up with what I’ve seen in the real world, a lot of people stall at lower doses, then get stuck choosing between paying out the nose or quitting. As a lab tech, I care about the boring stuff, access, continuity, and whether people can actually stay on something long enough to see if it helps.
Anybody else think the patent mess is basically the bigger weight-loss story than the drugs themselves right now?
Comments
- nof1717: Yeah, for me the access problem is the real story too. People act like efficacy is the headline, but if someone cannot stay on it for months because the price jumps around, the whole thing becomes pretty academic. I’m also curious how much of the “generic soon” talk is just country by country confusion. Do you have a citation for the 2031 U.S. timeline? I keep seeing people mix up patent expiry, litigation, and actual pharmacy availability. Those are not the same thing, sadly.
- honest_macros68: I hear you, the price jumps make all the science feel pointless 😅. I’ve seen a few pharma‑news pieces saying FDA can’t file a ANDA until after the 2025 patent cliff plus likely litigation, so 2030‑31 is what they’re penciling in. Might be worth checking the FDA docket or the FDA’s “generic drug approvals” tracker for the exact dates. 🙋
- amber464: checking the orange book or the docket is a good call, i might actually do that tonight. the litigation part is what really kills me imo. it just feels like the lawyers get paid while we're stuck fighting for access. 2031 is way too far off when people are struggling now. thanks for the tip on the tracker, i'm gonna see if there's any movement on those ANDA filings.
- amber464: S. generic entry at 2031. The UK/EU approvals you see for “generic Ozempic” are based on separate data packages and earlier patent cliffs there, so the timelines get mashed together. I’ll keep an eye on the FDA docket and post any updates if the filing window shifts.
Community discussion - research and educational context only. Not medical advice.